renin
angiotensin
system
ra
consist
system
hormon
system
critic
involv
regul
homeostasi
normal
physiolog
function
ie
blood
pressur
bp
blood
volum
regul
independ
brain
ra
involv
regul
mani
function
memori
central
control
bp
metabol
function
gener
term
ra
consist
two
oppos
axe
classic
axi
mediat
primarili
angiotensin
ii
ang
ii
altern
axi
mediat
mainli
angiotensin
ang
imbal
two
oppos
axe
thought
exist
gender
thought
contribut
patholog
cardiovascular
condit
hypertens
stroke
comorbid
ischaem
stroke
pathophysiolog
shown
influenc
compon
ra
specif
ra
receptor
antagonist
agonist
improv
outcom
experiment
model
stroke
manipul
two
oppos
axe
follow
acut
ischaem
stroke
may
provid
opportun
protect
neurovascular
unit
particularli
presenc
preexist
comorbid
balanc
may
shift
present
review
give
overview
experiment
stroke
studi
investig
pharmacolog
intervent
ra
uk
stroke
fourth
lead
caus
death
one
largest
contributor
toward
longterm
disabl
affect
approxim
peopl
everi
year
http
wwwstrokeorguk
state
nation
past
year
number
stroke
fatal
decreas
howev
estim
twothird
stroke
survivor
requir
daili
medic
care
half
left
disabl
result
annual
cost
nearli
billion
account
approxim
total
nh
expenditur
recombin
tissu
plasminogen
activ
rtpa
alteplas
thrombolyt
treatment
current
avail
acut
ischaem
stroke
ai
act
break
clot
thrombu
obstruct
cerebr
vessel
thu
reestablish
blood
flow
howev
narrow
therapeut
time
window
h
stroke
onset
result
ischaem
stroke
treat
global
detriment
side
effect
includ
haemorrhag
recent
result
number
randomis
clinic
trial
mechan
thrombectomi
demonstr
efficaci
intervent
h
stroke
onset
posit
result
trial
reinvigor
stroke
commun
open
new
possibl
adjunct
protect
strategi
failur
translat
effect
therapeut
strategi
bench
bedsid
may
partli
attribut
use
anim
model
incorpor
nonmodifi
risk
factor
gender
mani
stroke
comorbid
observ
clinic
stroke
popul
hypertens
diabet
obes
etc
instanc
hypertens
singl
import
modifi
risk
factor
stroke
act
contribut
factor
first
time
stroke
patient
hypertens
acut
stroke
associ
poorer
clinic
outcom
renin
angiotensin
system
ra
peptid
hormon
system
intrins
involv
blood
pressur
regul
blood
volum
homeostasi
circul
shown
present
local
paracrin
system
brain
ra
report
involv
patholog
ai
risk
factor
therefor
emerg
potenti
therapeut
target
review
discuss
therapeut
potenti
ra
follow
ai
emphasis
import
cerebr
ra
receptor
target
relev
presenc
known
stroke
risk
factor
circul
drop
blood
pressur
system
hypotens
andor
blood
volum
result
juxtaglomerular
cell
within
kidney
releas
renin
proteas
wherea
increas
blood
pressur
hypertens
inhibit
renin
releas
normal
circumst
circul
angiotensinogen
hydrolys
renin
produc
angiotensin
ang
convert
angiotensin
convert
enzym
ace
gener
biolog
activ
octapeptid
ang
ii
fig
ang
ii
potent
vasoconstrictor
act
stimul
ang
ii
type
type
receptor
r
r
ang
ii
exhibit
higher
affin
wide
express
r
wherebi
exert
main
physiolog
effect
constrict
blood
vessel
increas
bp
stimul
aldosteron
releas
adren
gland
promot
water
salt
reabsorpt
kidney
thu
rais
blood
volum
level
last
decad
altern
axi
identifi
involv
monocarboxypeptidas
biolog
activ
peptid
ang
gprotein
coupl
receptor
ma
masr
ang
form
direct
action
ang
ii
via
induc
cleavag
ang
gener
nine
amino
acid
peptid
ang
convert
ang
ace
peptidas
neprilysin
nep
compon
classic
axi
angiotensinogen
renin
ace
ang
ii
identifi
within
brain
parenchyma
see
review
addit
evid
altern
axi
local
produc
within
brain
localis
neuron
astrocyt
within
cerebrovasculatur
similarli
receptor
subtyp
respons
mediat
function
effect
ra
peptid
express
neuron
glial
cell
throughout
brain
exampl
receptor
shown
present
dopaminerg
neuron
astrocyt
microglia
human
primat
brain
tissu
masr
shown
express
neuron
astrocyt
microglia
cerebr
endotheli
cell
rodent
overactiv
aceang
iiat
r
axi
thought
contribut
pathogenesi
ai
vasoconstrictor
effect
cerebr
vessel
well
proinflammatori
profibrot
increas
oxid
stress
effect
parenchyma
instanc
brain
r
knockout
ko
mice
subject
perman
middl
cerebr
arteri
occlus
pmcao
exhibit
larger
metabol
penumbra
volum
cerebr
protein
synthesi
atp
mismatch
higher
cbf
within
core
penumbra
compar
wild
type
wt
mice
wherea
mice
overexpress
human
renin
angiotensinogen
gene
larger
infarct
furthermor
ang
ii
shown
enhanc
contractil
respons
isol
middl
cerebr
arteri
mca
follow
mcao
via
r
therefor
worsen
cerebr
perfus
follow
ischaemia
interestingli
emerg
evid
identifi
altern
axi
endogen
protect
system
act
counteract
effect
classic
axi
mediat
vasodil
antiinflammatori
antioxid
antiapoptot
effect
via
masr
r
activ
follow
focal
cerebr
ischaemia
rat
rs
shown
upregul
periinfarct
region
cortex
also
within
select
vulner
region
cortex
hippocampu
follow
global
cerebr
ischaemia
r
ko
mice
exhibit
less
ischaem
damag
compar
wt
control
anim
follow
mcao
suggest
protect
role
receptor
set
cerebr
ischaemia
support
role
pathway
follow
acut
ischaem
stroke
ma
axi
shown
upregul
brain
express
mrna
protein
level
masr
upregul
earli
h
follow
perman
mcao
rat
peak
h
post
mcao
associ
concomit
increas
circul
serum
cerebr
ang
level
increas
occur
first
critic
hour
stroke
ischaem
damag
loss
potenti
salvag
penumbra
take
place
suggest
potenti
role
pathway
pathogenesi
increas
exogen
ang
level
brain
central
infus
prior
stroke
shown
decreas
infarct
volum
rat
provid
evid
protect
role
pathway
poststrok
current
evid
suggest
imbal
ra
follow
stroke
enhanc
activ
aceang
iiat
r
pathway
target
counterregulatori
ma
axi
may
provid
protect
imbal
ra
may
exacerb
presenc
known
stroke
risk
factor
gender
hypertens
therefor
provid
potenti
therapeut
target
subset
patient
men
higher
incid
stroke
howev
menopaus
incid
stroke
women
rapidli
increas
coincid
decreas
femal
sex
hormon
addit
sex
differ
stroke
incid
also
well
establish
experiment
stroke
studi
femal
anim
less
ischaem
injuri
male
counterpart
protect
lost
ovariectomi
furthermor
cell
exhibit
sex
specif
differ
specif
mechan
cell
death
follow
cerebr
ischaemia
therefor
unlik
sex
differ
exist
ra
brain
elsewher
wide
accept
ra
influenc
sex
hormon
male
femal
exhibit
differenti
respons
stimul
inhibit
ra
differ
vascular
reactiv
ang
ii
receptor
express
shown
influenc
sex
hormon
testosteron
stimul
classic
axi
oestrogen
lower
r
r
ratio
therebi
enhanc
vasodilat
interestingli
experiment
anim
model
femal
rat
exhibit
enhanc
activ
ma
axi
compar
male
show
increas
renal
ang
level
find
may
translat
human
normotens
healthi
adult
femal
shown
higher
plasma
level
ang
male
counterpart
combin
find
suggest
oestrogen
may
confer
degre
protect
stroke
premenopaus
women
promot
increas
activ
ma
axi
therefor
loss
oestrogen
associ
menopaus
may
simplifi
overview
renin
angiotensin
system
ra
angiotensinogen
cleav
renin
gener
angiotensin
ang
form
angiotensin
ii
ang
ii
via
action
angiotensin
convert
enzym
ace
ang
ii
preferenti
bind
angiotensin
ii
type
receptor
r
classic
axi
induc
vasoconstrict
inflamm
oxid
stress
apoptosi
cell
prolifer
ang
ii
also
activ
angiotensin
ii
type
ii
r
metabolis
angiotensin
convert
enzym
gener
angiotensin
ang
activ
ma
receptor
masr
ang
form
action
ace
neprilysin
nep
angiotensin
angiotensin
r
masr
form
altern
axi
activ
thought
counteract
detriment
effect
induc
r
lead
vasodil
angiogenesi
prevent
inflamm
oxid
stress
apoptosi
contribut
increas
stroke
risk
loss
enhanc
protect
pathway
term
brain
express
r
express
shown
lower
rat
treat
oestrogen
plu
ovariectomi
compar
ovariectomi
alon
contrast
oestrogen
treatment
ovariectomis
rat
result
increas
express
r
compar
ovariectomis
rat
similarli
mrna
express
r
ace
increas
brain
hypertens
ovariectomis
rat
compar
intact
femal
hypertens
singl
import
modifi
risk
factor
develop
stroke
clinic
outcom
poorer
patient
hypertens
acut
stroke
experiment
anim
model
stroke
ischaem
damag
significantli
increas
hypertens
anim
dysregul
ra
implic
develop
hypertens
hyperact
ang
ii
ra
compon
lead
enhanc
oxid
stress
inflamm
preclin
model
genet
hypertens
demonstr
increas
r
express
vasculatur
spontan
hypertens
rat
shr
compar
agematch
normotens
control
addit
hyperact
classic
axi
dampen
protect
counterregulatori
axi
also
evid
hypertens
rat
strain
exhibit
decreas
mrna
protein
express
compar
normotens
control
chronic
treatment
diabet
shr
rat
either
r
blocker
olmesartan
ace
inhibitor
enalapril
revers
microcirculatori
chang
occur
pial
vessel
function
structur
rarefact
brain
result
improv
cerebr
perfus
reduc
cerebr
oxid
stress
candesartan
treatment
salt
load
shrsp
rat
shown
increas
endotheli
cell
progenitor
epc
coloni
number
reduc
oxid
stress
level
mononuclear
cell
studi
suggest
arb
treatment
may
also
act
improv
endotheli
cell
function
angiogenesi
presenc
hypertens
result
demonstr
influenc
aceang
ii
pathway
remodel
cerebr
microvasculatur
suggest
overactiv
pathway
may
contribut
patholog
therefor
manipul
ra
toward
protect
masr
pathway
presenc
comorbid
may
shift
balanc
prevent
exacerb
ischaem
damag
follow
ai
angiotensin
type
receptor
blocker
arb
sartan
wide
use
success
establish
therapi
treatment
clinic
hypertens
result
class
drug
assess
possibl
neuroprotect
effect
number
experiment
stroke
studi
tabl
central
administr
irbesartan
arb
prior
transient
middl
cerebr
arteri
occlus
tmcao
shown
improv
neurolog
outcom
effect
blood
pressur
howev
one
limit
lack
measur
infarct
volum
follow
studi
demonstr
administr
arb
prior
mcao
could
fact
reduc
infarct
volum
associ
reduct
number
activ
microglia
macrophag
stain
well
reduct
marker
apoptosi
tunel
parp
stain
caspas
cerebr
vasodilatori
potenti
arb
extens
investig
studi
examin
effect
isol
cerebr
vessel
well
cerebr
blood
flow
cbf
respons
vivo
candesartan
particular
shown
potenti
increas
cerebr
perfus
follow
mcao
normotens
well
hypertens
rat
shr
normotens
rat
administr
candesartan
iv
bolu
h
prior
mcao
report
increas
cbf
ipsilater
hemispher
baselin
mcao
shr
chronic
candesartan
infus
day
prior
mcao
reduc
infarct
volum
associ
improv
cbf
compar
vehicl
treat
rat
particularli
cortic
area
peripheri
infarct
addit
isol
vessel
taken
end
chronic
treatment
protocol
demonstr
increas
mca
diamet
reduc
media
thick
suggest
chronic
chang
cerebr
vessel
result
reduc
hypertens
induc
remodel
enhanc
collater
flow
similarli
nishimura
colleagu
demonstr
chronic
pretreat
candesartan
improv
cerebrovascular
autoregul
decreas
infarct
size
outcom
associ
reduc
r
bind
mca
ang
ii
autoradiographi
report
effect
r
blockad
includ
proangiogenicneurogen
effect
exampl
candesartan
pretreat
dose
bp
effect
reduc
infarct
volum
increas
mrna
express
brain
deriv
neurotroph
factor
bdnf
associ
receptor
tropomyosin
receptor
kinas
b
trkb
h
tmcao
similarli
shr
rat
candesartan
treatment
follow
mcao
shown
increas
bdnf
protein
level
suggest
potenti
involv
neuron
cell
regener
despit
indic
neuroprotect
blockad
r
experiment
studi
attenu
infarct
evolut
independ
bp
lower
effect
tabl
propos
neuroprotect
mechan
induc
arb
may
partli
involv
increas
ang
ii
bind
receptor
consequ
select
r
agonist
develop
investig
model
experiment
stroke
tabl
normotens
rat
central
system
administr
compound
select
nonpeptid
oral
activ
r
agonist
prior
post
induc
mcao
reduc
infarct
size
improv
neurolog
deficit
protect
effect
attribut
decreas
inflammatori
marker
induc
nitric
oxid
synthas
ino
cc
motif
chemokin
receptor
type
mrna
express
cerebr
cortex
follow
tmcao
effect
block
r
select
antagonist
consciou
shr
rat
r
agonist
attenu
lesion
progress
improv
motor
function
follow
tmcao
effect
independ
bp
alter
possibl
due
enhanc
r
receptor
level
express
increas
microgli
activ
reduc
superoxid
product
within
periinfarct
region
find
support
vitro
data
primari
cortic
neuron
administr
shown
attenu
cell
death
follow
oxygen
glucos
deprav
ogd
similarli
shown
dose
depend
reduc
infarct
volum
shr
administ
central
day
prior
endothelin
induc
mcao
associ
increas
microglia
activ
within
infarct
core
periinfarct
howev
administ
h
poststrok
protect
effect
still
observ
enhanc
microgli
activ
apart
antiinflammatori
role
also
shown
promot
angiogenesi
primari
cortic
neuron
treatment
h
post
ogd
challeng
enhanc
vascular
endotheli
growth
factor
vegf
via
mechanist
target
rapamycin
mtor
pathway
activ
similarli
vivo
model
day
treatment
mice
subject
either
transient
perman
mcao
result
increas
angiogenesi
via
vegf
upregul
effect
author
hypothesis
r
mediat
activ
pathway
addit
ex
vivo
studi
vasodil
increas
perfus
seem
depend
anim
model
use
use
wire
myographi
treatment
isol
basilar
arteri
caus
cerebr
vessel
relax
promot
vasodil
outcom
support
vivo
studi
mice
subject
pmcao
pretreat
improv
cbf
ischaem
hemispher
day
follow
pmcao
associ
decreas
infarct
size
attenu
blood
brain
barrier
bbb
breakdown
measur
evan
blue
extravas
contrari
mice
subject
tmcao
induc
acut
chang
cbf
administ
follow
reperfus
contrast
protect
effect
discuss
recent
studi
show
affect
infarct
volum
mice
day
follow
tmcao
howev
improv
neurolog
score
mortal
rate
interestingli
neurolog
improv
observ
associ
increas
antiapoptot
regen
molecul
bdnf
trkb
growth
associ
protein
periinfarct
region
compar
vehicl
evid
suggest
r
interact
ra
mediat
effect
may
partli
mediat
interact
ma
receptor
activ
ang
recent
interact
ang
masr
ai
studi
shown
protect
sever
anim
model
tabl
mecca
colleagu
one
first
group
identifi
potenti
neuroprotect
effect
peptid
receptor
demonstr
central
administr
ang
day
prior
induc
mcao
reduc
infarct
volum
via
masr
activ
decreas
cortic
ino
mrna
express
evid
propos
ang
might
direct
antiinflammatori
properti
specif
target
microglia
primari
microgli
cell
cultur
basal
condit
masr
activ
modul
inflammatori
marker
express
attenu
proinflammatori
gene
follow
tmcao
injuri
ang
treatment
reduc
ino
mrna
protein
level
ipsilater
cerebr
cortex
attenu
chemokin
cxc
motif
ligand
level
h
post
tmcao
interleukin
il
cluster
differenti
h
find
support
pmcao
studi
ang
decreas
nuclear
factor
kappa
b
phosphoryl
protein
level
periinfarct
region
compar
vehicl
vasodilatori
properti
ang
cerebr
vessel
conflict
canin
mca
piglet
pial
arteriol
ang
induc
vasodil
intact
vessel
high
concentr
howev
durand
colleagu
demonstr
normotens
isol
rat
mca
ang
dose
depend
induc
vasodil
respons
block
ma
receptor
antagonist
ang
mediat
vasodilat
may
vari
depend
anim
speci
nevertheless
rodent
possibl
studi
involv
either
transient
middl
cerebr
arteri
tmcao
perman
middl
cerebr
arteri
occlus
pmcao
unless
specifi
tmcao
perform
via
intralumin
filament
model
akt
protein
kinas
b
r
angiotensin
ii
type
receptor
r
angiotensin
ii
type
ii
receptor
bbb
blood
brain
barrier
bdnf
brain
deriv
neurotroph
factor
bht
behaviour
test
bp
blood
pressur
compound
cbf
cerebr
blood
flow
chemokin
cc
motif
ligand
cc
chemokin
receptor
type
cyclooxygenas
dmcao
distal
middl
cerebr
arteri
occlus
model
eno
endotheli
nitric
oxid
synthas
icv
intracerebroventricular
interleukin
ino
induc
nitric
oxid
synthas
ip
intraperiton
macrophag
chemokin
protein
mri
magnet
reson
imag
mtor
mechanist
target
rapamycin
neun
neuron
nuclei
nitric
oxid
ns
neurolog
score
antibodi
pakt
phosphoryl
akt
shr
spontan
hypertens
rat
superoxid
tumor
necrosi
factor
alpha
trkb
tropomyosin
receptor
kinas
b
ttc
chlorid
stain
vegf
vascular
endotheli
growth
factor
ang
might
induc
vasodil
cerebr
vessel
due
increas
andor
bradykinin
bk
releas
central
administr
ang
rat
transient
mcao
model
shown
enhanc
nitric
oxid
releas
h
transient
mcao
compar
vehicl
treat
rat
associ
increas
mrna
protein
express
endotheli
nitric
oxid
synthas
eno
ischaem
brain
tissu
acut
time
point
follow
mcao
addit
concentr
level
bk
receptor
shown
upregul
ischaem
cortex
follow
ang
treatment
h
post
tmcao
similarli
chronic
ang
infus
prior
mcao
shown
increas
protein
level
eno
concentr
ischaem
hemispher
wherea
ino
neuron
nno
express
unchang
interestingli
brain
vegf
protein
level
also
elev
outcom
associ
increas
angiogen
marker
edu
follow
pmcao
ang
reduc
infarct
volum
improv
cbf
effect
specif
masr
suggest
ang
activ
maseno
signal
pathway
improv
angiogenesi
cerebr
perfus
still
impact
ang
cbf
debat
mecca
et
al
report
central
infus
ang
day
prior
induc
mcao
affect
cbf
measur
mcao
target
masr
ang
show
promis
result
experiment
stroke
model
howev
ang
half
life
bloodstream
unlik
cross
bbb
therefor
necessit
specif
receptor
agonist
develop
improv
pharmacokinet
profil
result
order
see
effect
follow
ai
administ
central
rout
administr
clinic
feasibl
present
ma
agonist
develop
howev
follow
tmcao
mice
ip
posttreat
fail
induc
similar
neuroprotect
observ
ang
treat
studi
clinic
trial
effect
arb
treatment
prevent
vascular
event
mortal
follow
ai
debat
life
trial
compar
losartan
r
antagonist
atenolol
select
receptor
blocker
treatment
prevent
cerebr
ischaem
event
patient
clinic
histori
hypertens
left
ventricular
hypertrophi
follow
time
year
author
demonstr
use
losartan
associ
decreas
frequenc
stroke
moreov
access
trial
design
assess
efficaci
modest
blood
pressur
reduct
acut
stroke
day
post
stroke
day
patient
receiv
either
candesartan
cilexetil
r
antagonist
placebo
treatment
although
trial
stop
earli
demonstr
reduc
number
vascular
event
decreas
mortal
candesartan
treatment
group
follow
year
mose
studi
investig
effect
eprosartan
nitrendipin
calcium
channel
blocker
hypertens
patient
cerebrovascular
event
within
last
month
prior
recruit
year
follow
identifi
eprosartan
group
show
significantli
less
case
cardiovascular
cerebrovascular
event
furthermor
telmisartan
altern
therapi
cardiovascular
diseas
patient
intoler
ace
inhibitor
shown
induc
modest
reduct
stroke
incid
despit
benefit
r
antagon
observ
studi
show
contradictori
effect
instanc
studi
assess
whether
blood
pressur
lower
telmisartan
treatment
ischaem
stroke
patient
affect
risk
recurr
cerebr
event
conclud
year
follow
telmisartan
affect
risk
recurr
stroke
cardiovascular
event
recent
scast
clinic
trial
investig
whether
blood
pressur
lower
candesartan
acut
stroke
patient
benefici
month
follow
benefici
effect
blood
pressur
lower
candesartan
observ
differ
occurr
vascular
event
plu
function
outcom
less
favour
modifi
rankin
score
candesartan
group
albeit
statist
signific
result
clinic
trial
date
primarili
investig
influenc
modul
ra
term
stroke
incid
blood
pressur
lower
strategi
follow
stroke
howev
effect
ra
modul
acut
ischaem
stroke
term
outcom
ie
penumbr
salvag
lesion
volum
yet
fulli
investig
ra
current
therapeut
target
treatment
ai
patholog
activ
classic
axi
contribut
toward
ischaem
injuri
develop
altern
axi
thought
counteract
effect
lead
protect
interestingli
patholog
stroke
comorbid
hypertens
gender
influenc
ra
dysfunct
increasedoveract
aceang
ii
r
pathway
consequ
target
ra
could
act
prevent
line
therapi
develop
stroke
attenu
injuri
follow
stroke
diminish
brain
ra
imbal
provid
direct
neuroprotect
sever
preclin
studi
identifi
potenti
neuroprotect
effect
r
blocker
r
masr
agonist
arb
extens
studi
context
experiment
stroke
due
current
clinic
use
hypertens
manag
although
indic
level
neuroprotect
induc
arb
clinic
potenti
set
asid
due
clinic
trial
show
arb
may
induc
harm
effect
ischaem
stroke
patient
hand
r
masr
agon
show
promis
effect
preclin
stroke
model
howev
studi
conduct
identifi
actual
mechan
induc
follow
stroke
address
sever
limit
associ
preclin
stroke
understand
role
ra
follow
ischaem
stroke
particular
role
ang
ma
pathway
develop
improv
pharmacolog
drug
target
central
ra
compon
need
success
translat
would
possibl
abbrevi
ace
angiotensin
convert
enzym
angiotensin
convert
enzym
ai
acut
ischaem
stroke
arb
angiotensin
type
receptor
blocker
angiotensin
type
receptor
angiotensin
type
receptor
bbb
blood
brain
barrier
bp
blood
pressur
cbf
cerebr
blood
flow
compound
receptor
agonist
epc
endotheli
progenitor
cell
ko
knockout
masr
ma
receptor
pmcao
perman
middl
cerebr
arteri
occlus
tmcao
transient
middl
cerebr
arteri
occlus
nep
neprilysin
nitric
oxid
ogd
oxygen
glucos
depriv
ra
renin
angiotensin
system
shr
spontan
hypertens
rat
wt
wild
type
vegf
vascular
endotheli
growth
factor
mmca
er
cm
contribut
review
literatur
critic
analysi
draft
manuscript
mmca
prepar
figur
tabl
author
read
approv
final
manuscript
